Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Depreciation & Amortization (CF): 2018-2025

Historic Depreciation & Amortization (CF) for Bicycle Therapeutics (BCYC) over the last 8 years, with Sep 2025 value amounting to $1.8 million.

  • Bicycle Therapeutics' Depreciation & Amortization (CF) fell 19.15% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 4.69%. This contributed to the annual value of $7.2 million for FY2024, which is 9.59% up from last year.
  • Latest data reveals that Bicycle Therapeutics reported Depreciation & Amortization (CF) of $1.8 million as of Q3 2025, which was up 3.54% from $1.7 million recorded in Q2 2025.
  • Bicycle Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $2.2 million for Q3 2024, and its period low was $325,000 during Q1 2021.
  • For the 3-year period, Bicycle Therapeutics' Depreciation & Amortization (CF) averaged around $1.7 million, with its median value being $1.7 million (2024).
  • Per our database at Business Quant, Bicycle Therapeutics' Depreciation & Amortization (CF) skyrocketed by 275.07% in 2022 and then dropped by 19.15% in 2025.
  • Bicycle Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $407,000 in 2021, then surged by 240.54% to $1.4 million in 2022, then climbed by 19.34% to $1.7 million in 2023, then increased by 3.02% to $1.7 million in 2024, then declined by 19.15% to $1.8 million in 2025.
  • Its Depreciation & Amortization (CF) was $1.8 million in Q3 2025, compared to $1.7 million in Q2 2025 and $1.6 million in Q1 2025.